Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

For more information, click below.


Subscribers log in here


Related articles

Immunizations during pregnancy

INTRODUCTION

Maternal immunization protects both the mother and fetus from the morbidity of certain infections. It can also provide the infant passive protection against infections acquired independently after birth [1]. Ideally, immunizations are given prior to conception, but administration during pregnancy is indicated in some situations.

Nonimmune women are immunized during pregnancy when there is a high risk of exposure to an infection, the infection is hazardous to mother or fetus, and the immunizing agent is unlikely to cause harm. Despite maternal immunological adaptations to pregnancy, immunization of pregnant women appears to be as effective as in nonpregnant women [2].

The Infectious Diseases Society of America has published general guidelines for immunization of pregnant women [3]:

  • Providers should be aware of immunizations routinely recommended for all pregnant women (tetanus, diphtheria, influenza) (see 'Routine immunizations' below).
  • Providers should administer appropriate vaccines to pregnant women with medical or exposure indications that put them at risk for vaccine preventable infections (see 'Selective immunization of high risk groups' below).
  • Following delivery, postpartum women should receive all recommended vaccines that could not be or were not administered during pregnancy (eg, measles/mumps/rubella, varicella, Tetanus toxoids diphtheria acellular pertussis vaccine [Tdap]) (see 'Postpartum immunization' below).
  • Providers should be aware of and follow contraindications and precautions for immunization of pregnant women.

Obstetrician-gynecologists are often the primary clinician for women of child-bearing age; as such, they are in a good position to screen for immunization status and to provide appropriate vaccinations. However, financial factors (eg, inadequate reimbursement, cost of storing vaccines) and knowledge about vaccine counseling, safety, and administration appear to be barriers to vaccine administration in OB/GYN offices [4,5].

                                       

Subscribers log in here

To continue reading this article you must have access through your hospital or your group practice, log in to your personal subscription, or purchase a personal subscription. For more information, click below.
Literature review current through: Apr 2013. | This topic last updated: Feb 21, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2013 UpToDate, Inc.
References
Top
  1. Englund JA. The influence of maternal immunization on infant immune responses. J Comp Pathol 2007; 137 Suppl 1:S16.
  2. Gonik B, Fasano N, Foster S. The obstetrician-gynecologist's role in adult immunization. Am J Obstet Gynecol 2002; 187:984.
  3. Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:817.
  4. Leddy MA, Anderson BL, Power ML, et al. Changes in and current status of obstetrician-gynecologists' knowledge, attitudes, and practice regarding immunization. Obstet Gynecol Surv 2009; 64:823.
  5. Akinsanya-Beysolow I, Wolfe CS. Update: Vaccines for women, adolescence through adulthood. J Womens Health (Larchmt) 2009; 18:1101.
  6. National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
  7. Preblud SR. Fetal risk associated with rubella vaccination during pregnancy. In: Infectious Diseases in Obstetrics and Gynecology, Third Edition, Monif GG (Ed), IDI Publications, Omaha, NE 1993. p.2-139.
  8. www.cdc.gov/vaccines/pubs/preg-guide.htm#1 (Accessed on October 01, 2007).
  9. Coonrod DV, Jack BW, Boggess KA, et al. The clinical content of preconception care: immunizations as part of preconception care. Am J Obstet Gynecol 2008; 199:S290.
  10. Committee on Adolescent Health Care, ACOG Working Group on Immunization. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol 2006; 108:699.
  11. Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). www.cdc.gov/mmwr/preview/mmwrhtml/rr56e312a1.htm (Accessed on March 20, 2007).
  12. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009; 114:1170.
  13. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114:1179.
  14. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626.
  15. www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf (Accessed on October 02, 2007).
  16. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.
  17. Siegel M, Fuerst HT. Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis. JAMA 1966; 197:680.
  18. St Geme JW Jr, Noren GR, Adams P Jr. Proposed embryopathic relation between mumps virus and primary endocardial fibroelastosis. N Engl J Med 1966; 275:339.
  19. Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome--United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279.
  20. Hahné S, Macey J, van Binnendijk R, et al. Rubella outbreak in the Netherlands, 2004-2005: high burden of congenital infection and spread to Canada. Pediatr Infect Dis J 2009; 28:795.
  21. Kakoulidou M, Forsgren M, Lewensohn-Fuchs I, Johansen K. Serum levels of rubella-specific antibodies in Swedish women following three decades of vaccination programmes. Vaccine 2010; 28:1002.
  22. Landes RD, Bass JW, Millunchick EW, Oetgen WJ. Neonatal rubella following postpartum maternal immunization. J Pediatr 1980; 97:465.
  23. Centers for Disease Control (CDC). Rubella vaccination during pregnancy--United States, 1971-1988. MMWR Morb Mortal Wkly Rep 1989; 38:289.
  24. Bar-Oz B, Levichek Z, Moretti ME, et al. Pregnancy outcome following rubella vaccination: a prospective controlled study. Am J Med Genet A 2004; 130A:52.
  25. Badilla X, Morice A, Avila-Aguero ML, et al. Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J 2007; 26:830.
  26. Centers for Disease Control and Prevention (CDC). Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:1117.
  27. Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330:901.
  28. Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol 2006; 21:410.
  29. Bai PV, John TJ. Congenital skin ulcers following varicella in late pregnancy. J Pediatr 1979; 94:65.
  30. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.
  31. Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343:1548.
  32. Shields KE, Galil K, Seward J, et al. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet Gynecol 2001; 98:14.
  33. Wilson E, Goss MA, Marin M, et al. Varicella vaccine exposure during pregnancy: data from 10 Years of the pregnancy registry. J Infect Dis 2008; 197 Suppl 2:S178.
  34. Bohlke K, Galil K, Jackson LA, et al. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? Obstet Gynecol 2003; 102:970.
  35. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996; 45:1.
  36. Huang W, Hussey M, Michel F. Transmission of varicella to a gravida via close contacts immunized with varicella-zoster vaccine. A case report. J Reprod Med 1999; 44:905.
  37. Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997; 131:151.
  38. www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf (Accessed on October 01, 2007).
  39. www.cdc.gov/nip/recs/provisional_recs/zoster-11-20-06.pdf (Accessed on October 01, 2007).
  40. Whitman C, Belgharbi L, Gasse F, et al. Progress towards the global elimination of neonatal tetanus. World Health Stat Q 1992; 45:248.
  41. Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet 2007; 370:1947.
  42. Gupta SD, Keyl PM. Effectiveness of prenatal tetanus toxoid immunization against neonatal tetanus in a rural area in India. Pediatr Infect Dis J 1998; 17:316.
  43. Centers for Disease Control and Prevention (CDC). Progress toward elimination of neonatal tetanus--Egypt, 1988-1994. MMWR Morb Mortal Wkly Rep 1996; 45:89.
  44. Meegan ME, Conroy RM, Lengeny SO, et al. Effect on neonatal tetanus mortality after a culturally-based health promotion programme. Lancet 2001; 358:640.
  45. Gerbie MV, Tan TQ. Pertussis disease in new mothers: effect on young infants and strategies for prevention. Obstet Gynecol 2009; 113:399.
  46. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23:985.
  47. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293.
  48. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011; 204:334.e1.
  49. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 2013; 56:539.
  50. Riley LE, Beigi RH. Editorial commentary: maternal pertussis vaccination: protecting neonates from infection. Clin Infect Dis 2013; 56:545.
  51. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007; 7:614.
  52. Committee on Obstetric Practice. ACOG Committee Opinion No. 521: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet Gynecol 2012; 119:690.
  53. Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).
  54. Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012; 207:59.e1.
  55. Halperin BA, Morris A, Mackinnon-Cameron D, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011; 53:885.
  56. Håberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.
  57. Tamma PD, Ault KA, del Rio C, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009; 201:547.
  58. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011; 204:146.e1.
  59. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2011; 205:473.e1.
  60. Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012; 344:e2794.
  61. Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 2012; 308:165.
  62. Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2005; 192:1098.
  63. Pool V, Iskander J. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2006; 194:1200; author reply 1201.
  64. MacDonald NE, Riley LE, Steinhoff MC. Influenza immunization in pregnancy. Obstet Gynecol 2009; 114:365.
  65. Roberts S, Hollier LM, Sheffield J, et al. Cost-effectiveness of universal influenza vaccination in a pregnant population. Obstet Gynecol 2006; 107:1323.
  66. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.
  67. Mak TK, Mangtani P, Leese J, et al. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008; 8:44.
  68. Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among pregnant women - 29 States and New York City, 2009-10 season. MMWR Morb Mortal Wkly Rep 2012; 61:113.
  69. Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among pregnant women: 2011-12 influenza season, United States. MMWR Morb Mortal Wkly Rep 2012; 61:758.
  70. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53:1.
  71. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 468: Influenza vaccination during pregnancy. Obstet Gynecol 2010; 116:1006.
  72. Prevention and Control of Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0729a1.htm?s_cid=rr59e0729a1_w .
  73. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007; 110:941.
  74. Sheffield JS, Hickman A, Tang J, et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol 2011; 117:1130.
  75. Elinav E, Ben-Dov IZ, Shapira Y, et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 2006; 130:1129.
  76. McDuffie RS Jr, Bader T. Fetal meconium peritonitis after maternal hepatitis A. Am J Obstet Gynecol 1999; 180:1031.
  77. Leikin E, Lysikiewicz A, Garry D, Tejani N. Intrauterine transmission of hepatitis A virus. Obstet Gynecol 1996; 88:690.
  78. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1.
  79. Quiambao BP, Nohynek HM, Käyhty H, et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007; 25:4470.
  80. Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, et al. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev 2012; 7:CD004903.
  81. http://www.cdc.gov/ncidod/dvbid/westnile/qa/insect_repellent.htm (Accessed on January 18, 2013).
  82. Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 1993; 87:337.
  83. Suzano CE, Amaral E, Sato HK, et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006; 24:1421.
  84. Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.
  85. Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993; 168:1520.
  86. Nishioka Sde A, Nunes-Araújo FR, Pires WP, et al. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 1998; 3:29.
  87. Robert E, Vial T, Schaefer C, et al. Exposure to yellow fever vaccine in early pregnancy. Vaccine 1999; 17:283.
  88. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51:1.
  89. Cavalcanti DP, Salomão MA, Lopez-Camelo J, et al. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 2007; 12:833.
  90. Centers for Disease Control and Prevention (CDC). Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:130.
  91. Centers for Disease Control and Prevention (CDC). Progress toward poliomyelitis eradication--Nigeria, January 2003-March 2004. MMWR Morb Mortal Wkly Rep 2004; 53:343.
  92. Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination. MMWR Morb Mortal Wkly Rep 1999; 48:590.
  93. Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.
  94. Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.
  95. Centers for Disease Control and Prevention (CDC). Women with smallpox vaccine exposure during pregnancy reported to the National Smallpox Vaccine in Pregnancy Registry--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:386.
  96. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003; 52:1.
  97. Suarez VR, Hankins GD. Smallpox and pregnancy: from eradicated disease to bioterrorist threat. Obstet Gynecol 2002; 100:87.
  98. Garde V, Harper D, Fairchok MP. Tertiary contact vaccinia in a breastfeeding infant. JAMA 2004; 291:725.
  99. Rotz LD, Dotson DA, Damon IK, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001; 50:1.
  100. Cono J, Casey CG, Bell DM, Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003; 52:1.
  101. Napolitano PG, Ryan MA, Grabenstein JD. Pregnancy discovered after smallpox vaccination: Is vaccinia immune globulin appropriate? Am J Obstet Gynecol 2004; 191:1863.
  102. www.bt.cdc.gov/agent/smallpox/vaccination/preg-factsheet.asp (Accessed on October 01, 2007).
  103. Sudarshan MK, Giri MS, Mahendra BJ, et al. Assessing the safety of post-exposure rabies immunization in pregnancy. Hum Vaccin 2007; 3:87.
  104. Use of Anthrax Vaccine in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e (Accessed on July 22, 2010).
  105. Ryan MA, Smith TC, Sevick CJ, et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol 2008; 168:434.
  106. CDC. Advisory Committee on Immunization Practices (ACIP) meeting minutes archive http://www.cdc.gov/vaccines/recs/acip/mtg-minutes-archive.htm (Accessed on July 22, 2010).
  107. Wiesen AR, Littell CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA 2002; 287:1556.
  108. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45:1.
  109. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.
  110. Black NA, Parsons A, Kurtz JB, et al. Post-partum rubella immunisation: a controlled trial of two vaccines. Lancet 1983; 2:990.
  111. Pavelka R, Salzer H, Reinold E. [Post partum rubella vaccination and anti-D prevention]. Zentralbl Gynakol 1978; 100:1025.
  112. Edgar WM, Hambling MH. Rubella vaccination and anti-D immunoglobulin administration in the puerperium. Br J Obstet Gynaecol 1977; 84:754.
  113. Maroni E, Kunz J, Rösli A, Munzinger J. [Investigations on the influence of Rh immunoglobulin prophylaxis on the immune response to postpartum rubella vaccination (author's transl)]. Geburtshilfe Frauenheilkd 1975; 35:821.
  114. Maroni E, Munzinger J. Postpartum rubella vaccination and anti-D prophylaxis. Br Med J 1975; 2:541.
  115. CDC. The Pink Book: Epidemiology and Prevention of Vaccine Preventable Diseases Updated 11th Edition, (May 2009) http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rubella.pdf (Accessed on March 10, 2011).
  116. Sample pdf for Varicella Zoster IgG Release Form (Cangene) (PDF - 113KB) www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm176029.htm (Accessed on April 20, 2010).
  117. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.
  118. Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.
  119. Centers for Disease Control and Prevention (CDC). FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012; 61:212.